Company / SG&A Expense
Tango Therapeutics, Inc. SG&A Expense History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$41.5M
FY2025
5-year range
$9.9M / $43.7M
FY2021-FY2025
Trend
-5.1%
vs FY2024
Sector context
#172 of 213
Health Care
What the data says
Tango Therapeutics, Inc.'s sg&a expense of $42M is lower than 81% of companies in the Health Care sector (FY2025). Increased from $36M to $42M over the past 2 years.
Based on SEC 10-K filings.
$42M in FY2025 with a 5-year CAGR of +33.3%.
Increased from $36M to $42M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +33.1%
- 5-Year CAGR
- +33.3%
- 10-Year CAGR
- -
Sector benchmark
Top 19% in Health CareTop 19% of 213This company $41.5M Sector average $722.3M
▼
-94.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +33.3%, indicating consistent growth.
- In FY2025, sg&a expense decreased 5.1% year-over-year.
- Ranks #172 out of 213 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2024.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $41.5M | -5.1% |
| FY2024 | $43.7M | +23.2% |
| FY2023 | $35.5M | +101.8% |
| FY2022 | $17.6M | +78.4% |
| FY2021 | $9.9M | +0.0% |
| FY2020 | $9.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026